Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-231-5660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.51 million
Profitability
Miscellaneous
Employees91
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable
Alector (NASDAQ:ALEC) Frequently Asked Questions
What is Alector's stock symbol?
Alector trades on the NASDAQ under the ticker symbol "ALEC."
How were Alector's earnings last quarter?
Alector Inc (NASDAQ:ALEC) posted its earnings results on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.07. The business had revenue of $2.70 million for the quarter. Alector had a negative return on equity of 58.27% and a negative net margin of 378.57%. View Alector's Earnings History.
When is Alector's next earnings date?
What price target have analysts set for ALEC?
7 brokers have issued 1-year price targets for Alector's stock. Their forecasts range from $26.00 to $28.00. On average, they anticipate Alector's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for Alector.
What is the consensus analysts' recommendation for Alector?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.
Has Alector been receiving favorable news coverage?
Media stories about ALEC stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alector earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Alector.
Are investors shorting Alector?
Alector saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 4,280,000 shares, an increase of 19.2% from the December 15th total of 3,590,000 shares. Based on an average trading volume of 342,900 shares, the short-interest ratio is currently 12.5 days. Currently, 10.5% of the shares of the stock are short sold. View Alector's Current Options Chain.
Who are some of Alector's key competitors?
Some companies that are related to Alector include argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and Denali Therapeutics (DNLI).
What other stocks do shareholders of Alector own?
Who are Alector's key executives?
Alector's management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
- Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
- Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
- Dr. Robert S. King, Chief Devel. Officer (Age 56)
- Dr. Asa Abeliovich M.D., Ph.D., Co-Founder
When did Alector IPO?
(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.
Who are Alector's major shareholders?
Alector's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.04%). Company insiders that own Alector stock include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul and Sabah Oney. View Institutional Ownership Trends for Alector.
Which institutional investors are buying Alector stock?
How do I buy shares of Alector?
Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alector's stock price today?
One share of ALEC stock can currently be purchased for approximately $23.28.
How big of a company is Alector?
Alector has a market capitalization of $1.60 billion and generates $27.51 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Alector employs 91 workers across the globe.View Additional Information About Alector.
What is Alector's official website?
How can I contact Alector?
Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]
MarketBeat Community Rating for Alector (NASDAQ ALEC)
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
